Ten-fold increase in death risk in individuals with high levels of myeloperoxidase, or MPO, compared to those with low levels, according to analysis of 3,700 patients of MDVIP tested by Quest Diagnostics
Read more at prnewswire.comhello world
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
